Literature DB >> 16618380

Preoperative and adjuvant treatment of localized rectal cancer.

Prajnan Das1, Christopher H Crane.   

Abstract

Although postoperative chemoradiation has a proven role in the treatment of stage II to III localized rectal cancer, recent trials have demonstrated the role of preoperative chemoradiation. A recent randomized trial has shown that preoperative chemoradiation yields higher rates of local control and sphincter preservation and lower rates of toxicity, compared with postoperative chemoradiation. Randomized trials have also shown that preoperative chemoradiation yields higher rates of pathologic complete response and local control, compared with radiotherapy alone. In this article, we review recent trials on preoperative and adjuvant therapy of localized rectal cancer. The roles of newer agents, such as capecitabine, oxaliplatin, and bevacizumab, are also discussed, and other key issues in the treatment of localized rectal cancer are reviewed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16618380     DOI: 10.1007/s11912-006-0016-6

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  40 in total

1.  Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate.

Authors:  Joakim Folkesson; Helgi Birgisson; Lars Pahlman; Bjorn Cedermark; Bengt Glimelius; Ulf Gunnarsson
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

2.  Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: a phase I study.

Authors:  Eric François; Marc Ychou; Michel Ducreux; Frédérique Bertheault-Cvitkovic; Marc Giovannini; Thierry Conroy; Claire Lemanski; Olivier Thomas; Valérie Magnin
Journal:  Eur J Cancer       Date:  2005-11-15       Impact factor: 9.162

3.  Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study.

Authors:  J-P Machiels; L Duck; B Honhon; B Coster; J-C Coche; P Scalliet; Y Humblet; S Aydin; J Kerger; V Remouchamps; J-L Canon; P Van Maele; L Gilbeau; S Laurent; C Kirkove; M Octave-Prignot; J-F Baurain; A Kartheuser; C Sempoux
Journal:  Ann Oncol       Date:  2005-10-11       Impact factor: 32.976

4.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

5.  Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.

Authors:  Claus Rödel; Peter Martus; Thomas Papadoupolos; Laszlo Füzesi; Martin Klimpfinger; Rainer Fietkau; Torsten Liersch; Werner Hohenberger; Rudolf Raab; Rolf Sauer; Christian Wittekind
Journal:  J Clin Oncol       Date:  2005-10-24       Impact factor: 44.544

6.  Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.

Authors:  N Wolmark; H S Wieand; D M Hyams; L Colangelo; N V Dimitrov; E H Romond; M Wexler; D Prager; A B Cruz; P H Gordon; N J Petrelli; M Deutsch; E Mamounas; D L Wickerham; E R Fisher; H Rockette; B Fisher
Journal:  J Natl Cancer Inst       Date:  2000-03-01       Impact factor: 13.506

7.  Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01.

Authors:  B Fisher; N Wolmark; H Rockette; C Redmond; M Deutsch; D L Wickerham; E R Fisher; R Caplan; J Jones; H Lerner
Journal:  J Natl Cancer Inst       Date:  1988-03-02       Impact factor: 13.506

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.

Authors:  Christopher G Willett; Yves Boucher; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Ricky T Tong; Daniel C Chung; Dushyant V Sahani; Sanjeeva P Kalva; Sergey V Kozin; Mari Mino; Kenneth S Cohen; David T Scadden; Alan C Hartford; Alan J Fischman; Jeffrey W Clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Helen X Chen; Paul C Shellito; Gregory Y Lauwers; Rakesh K Jain
Journal:  Nat Med       Date:  2004-01-25       Impact factor: 53.440

10.  Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer.

Authors:  G Klautke; P Feyerherd; K Ludwig; F Prall; T Foitzik; R Fietkau
Journal:  Br J Cancer       Date:  2005-04-11       Impact factor: 7.640

View more
  3 in total

1.  Prognostic value of Smac expression in rectal cancer patients treated with neoadjuvant therapy.

Authors:  Hongjiang Yan; Jinming Yu; Renben Wang; Shumei Jiang; Kunli Zhu; Dianbin Mu; Zhongfa Xu
Journal:  Med Oncol       Date:  2011-01-25       Impact factor: 3.064

2.  Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma.

Authors:  Chiaojung Jillian Tsai; Christopher H Crane; John M Skibber; Miguel A Rodriguez-Bigas; George J Chang; Barry W Feig; Cathy Eng; Sunil Krishnan; Dipen M Maru; Prajnan Das
Journal:  Cancer       Date:  2011-02-15       Impact factor: 6.860

3.  Predictive value of Smac, VEGF and Ki-67 in rectal cancer treated with neoadjuvant therapy.

Authors:  Hongjiang Yan; Renben Wang; Jinming Yu; Shumei Jiang; Kunli Zhu; Dianbin Mu; Zhongfa Xu
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.